FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Phanstiel S. Louise						2. Issuer Name and Ticker or Trading Symbol MYRIAD GENETICS INC [MYGN]								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last)		irst)	(Middle))		3. Date of Earliest Transaction (Month/Day/Year) 08/05/2021								X	Officer (give title below)		Other (spec below)		·	
(Street) SALT LA	AKE U	Т	84108		4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)																	
		Tak	ole I - I	Non-Deri	ivativ	e Se	curit	ies A	cquire	ed, D	isposed c	of, or B	enefic	ially	Owned					
1. Title of Security (Instr. 3)		2. Transac Date (Month/Da		Execution Date,		Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an		(A) or 3, 4 and	Benefi Owner		ties cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
						Code	v	Amount	(A) or (D) Price			Reported Transaction(s) (Instr. 3 and 4)								
Common Stock				08/05/2	08/05/2021		L		М		30,000	A	\$25	.39	109	109,527		D		
Common Stock				08/05/2021				S		47,881	D	\$35.03	398(1)	61	51,646		D			
Common	Stock			08/05/2	2021				M		30,000	A	\$21	.29	91	91,646		D		
Common Stock															21,000		I	The Phanstiel Trust		
			Table								sposed of, , converti				wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		if any	emed ion Date, //Day/Year)	4. Transa Code (8)				6. Date Exel Expiration I (Month/Day			7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)		D S	3. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Owner Form: Direct or Indi (I) (Inst	Ownership	Beneficial Ownership oct (Instr. 4)	
					Code	V (A)		(D)	Date Exercisable		Expiration Date	Title	Amou or Numi of Share	ber						
Non- Qualified Stock Option (right to buy)	\$21.29	08/05/2021			M			30,000	((2)	12/02/2021	Commo Stock	ⁿ 30,0	00	\$0.0	0		D		
Non- Qualified Stock Option (right to	\$25.39	08/05/2021			M			30,000	((2)	12/05/2021	Commo	ⁿ 30,0	00	\$0.0	0		D		

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$34.49 to \$35.50, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. The shares subject to this option are fully vested and exercisable.

By: Nathan A. Smith For: S. Louise Phanstiel

08/06/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).